Ophthalmic infections and their anti-infective challenges

Eduardo C Alfonso, Julie Crider

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

This introduction provides an overview of the succeeding articles contained within this supplement on the new fourth-generation fluoroquinolone antibiotic product, moxifloxacin ophthalmic solution 0.5% (VIGAMOX®, Alcon Laboratories, Inc., Fort Worth, TX). Moxifloxacin was developed specifically to address the increasing incidence of resistance to earlier-generation antibiotic molecules. Structural modifications to the moxifloxacin molecule have decreased the likelihood of the development of resistant organisms. This antibiotic has been shown to possess greater activity than previous-generation molecules against gram-positive bacteria while maintaining excellent potency against gram-negative organisms and nontuberculous (atypical) mycobacteria. Moxifloxacin ophthalmic solution 0.5% exhibits enhanced bioavailability due to a unique molecular structure that combines high lipophilicity for enhanced corneal penetration with high aqueous solubility at physiological pH. Numerous studies have shown that moxifloxacin ophthalmic solution 0.5% has high potency against a broad range of microbial species and a favorable profile in terms of safety and tolerability. The results presented in this supplement provide additional evidence for the potential benefits of moxifloxacin ophthalmic solution 0.5% in surgical prophylaxis and treatment of sight-threatening infections, such as bacterial conjunctivitis, endophthalmitis and keratitis.

Original languageEnglish
JournalSurvey of Ophthalmology
Volume50
Issue number6 SUPPL. 1
DOIs
StatePublished - Nov 1 2005

Fingerprint

Eye Infections
Ophthalmic Solutions
Nontuberculous Mycobacteria
Anti-Bacterial Agents
Bacterial Conjunctivitis
Endophthalmitis
Keratitis
Fluoroquinolones
Gram-Positive Bacteria
Molecular Structure
Solubility
Biological Availability
moxifloxacin
Safety
Incidence
Infection

Keywords

  • Anti-infectives
  • Antibiotic
  • Moxifloxacin
  • Penetration
  • Potency
  • Safety
  • Therapy
  • VIGAMOX®

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ophthalmic infections and their anti-infective challenges. / Alfonso, Eduardo C; Crider, Julie.

In: Survey of Ophthalmology, Vol. 50, No. 6 SUPPL. 1, 01.11.2005.

Research output: Contribution to journalArticle

@article{ad9cbb1f53c8467bacb447c581145ed0,
title = "Ophthalmic infections and their anti-infective challenges",
abstract = "This introduction provides an overview of the succeeding articles contained within this supplement on the new fourth-generation fluoroquinolone antibiotic product, moxifloxacin ophthalmic solution 0.5{\%} (VIGAMOX{\circledR}, Alcon Laboratories, Inc., Fort Worth, TX). Moxifloxacin was developed specifically to address the increasing incidence of resistance to earlier-generation antibiotic molecules. Structural modifications to the moxifloxacin molecule have decreased the likelihood of the development of resistant organisms. This antibiotic has been shown to possess greater activity than previous-generation molecules against gram-positive bacteria while maintaining excellent potency against gram-negative organisms and nontuberculous (atypical) mycobacteria. Moxifloxacin ophthalmic solution 0.5{\%} exhibits enhanced bioavailability due to a unique molecular structure that combines high lipophilicity for enhanced corneal penetration with high aqueous solubility at physiological pH. Numerous studies have shown that moxifloxacin ophthalmic solution 0.5{\%} has high potency against a broad range of microbial species and a favorable profile in terms of safety and tolerability. The results presented in this supplement provide additional evidence for the potential benefits of moxifloxacin ophthalmic solution 0.5{\%} in surgical prophylaxis and treatment of sight-threatening infections, such as bacterial conjunctivitis, endophthalmitis and keratitis.",
keywords = "Anti-infectives, Antibiotic, Moxifloxacin, Penetration, Potency, Safety, Therapy, VIGAMOX{\circledR}",
author = "Alfonso, {Eduardo C} and Julie Crider",
year = "2005",
month = "11",
day = "1",
doi = "10.1016/j.survophthal.2005.05.001",
language = "English",
volume = "50",
journal = "Survey of Ophthalmology",
issn = "0039-6257",
publisher = "Elsevier USA",
number = "6 SUPPL. 1",

}

TY - JOUR

T1 - Ophthalmic infections and their anti-infective challenges

AU - Alfonso, Eduardo C

AU - Crider, Julie

PY - 2005/11/1

Y1 - 2005/11/1

N2 - This introduction provides an overview of the succeeding articles contained within this supplement on the new fourth-generation fluoroquinolone antibiotic product, moxifloxacin ophthalmic solution 0.5% (VIGAMOX®, Alcon Laboratories, Inc., Fort Worth, TX). Moxifloxacin was developed specifically to address the increasing incidence of resistance to earlier-generation antibiotic molecules. Structural modifications to the moxifloxacin molecule have decreased the likelihood of the development of resistant organisms. This antibiotic has been shown to possess greater activity than previous-generation molecules against gram-positive bacteria while maintaining excellent potency against gram-negative organisms and nontuberculous (atypical) mycobacteria. Moxifloxacin ophthalmic solution 0.5% exhibits enhanced bioavailability due to a unique molecular structure that combines high lipophilicity for enhanced corneal penetration with high aqueous solubility at physiological pH. Numerous studies have shown that moxifloxacin ophthalmic solution 0.5% has high potency against a broad range of microbial species and a favorable profile in terms of safety and tolerability. The results presented in this supplement provide additional evidence for the potential benefits of moxifloxacin ophthalmic solution 0.5% in surgical prophylaxis and treatment of sight-threatening infections, such as bacterial conjunctivitis, endophthalmitis and keratitis.

AB - This introduction provides an overview of the succeeding articles contained within this supplement on the new fourth-generation fluoroquinolone antibiotic product, moxifloxacin ophthalmic solution 0.5% (VIGAMOX®, Alcon Laboratories, Inc., Fort Worth, TX). Moxifloxacin was developed specifically to address the increasing incidence of resistance to earlier-generation antibiotic molecules. Structural modifications to the moxifloxacin molecule have decreased the likelihood of the development of resistant organisms. This antibiotic has been shown to possess greater activity than previous-generation molecules against gram-positive bacteria while maintaining excellent potency against gram-negative organisms and nontuberculous (atypical) mycobacteria. Moxifloxacin ophthalmic solution 0.5% exhibits enhanced bioavailability due to a unique molecular structure that combines high lipophilicity for enhanced corneal penetration with high aqueous solubility at physiological pH. Numerous studies have shown that moxifloxacin ophthalmic solution 0.5% has high potency against a broad range of microbial species and a favorable profile in terms of safety and tolerability. The results presented in this supplement provide additional evidence for the potential benefits of moxifloxacin ophthalmic solution 0.5% in surgical prophylaxis and treatment of sight-threatening infections, such as bacterial conjunctivitis, endophthalmitis and keratitis.

KW - Anti-infectives

KW - Antibiotic

KW - Moxifloxacin

KW - Penetration

KW - Potency

KW - Safety

KW - Therapy

KW - VIGAMOX®

UR - http://www.scopus.com/inward/record.url?scp=27844546833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844546833&partnerID=8YFLogxK

U2 - 10.1016/j.survophthal.2005.05.001

DO - 10.1016/j.survophthal.2005.05.001

M3 - Article

VL - 50

JO - Survey of Ophthalmology

JF - Survey of Ophthalmology

SN - 0039-6257

IS - 6 SUPPL. 1

ER -